A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer

NCT05249426 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

48

Enrollment

INDUSTRY

Sponsor class

Conditions

Head and Neck Squamous Cell Carcinoma (HNSCC)

Interventions

DRUG: BI 765063
DRUG: Ezabenlimab
DRUG: BI 836880
DRUG: Cetuximab
OTHER: Investigator´s Choice Chemotherapy

Sponsor

Boehringer Ingelheim